Modality
mRNA
MOA
BTKi
Target
CD123
Pathway
Tau
Meso
Development Pipeline
Preclinical
~Nov 2017
→ ~Feb 2019
Phase 1
~May 2019
→ ~Aug 2020
Phase 2
Nov 2020
→ Apr 2026
Phase 2Current
NCT03774341
2,403 pts·Meso
2020-11→2026-04·Active
2,403 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-04-101w awayPh2 Data· Meso
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2
P2
Active
Catalysts
Ph2 Data
2026-04-10 · 1w away
Meso
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03774341 | Phase 2 | Meso | Active | 2403 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| AZN-8281 | AstraZeneca | Phase 1 | SHP2 | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| NVO-7872 | Novo Nordisk | NDA/BLA | B7-H3 | |
| NVO-6275 | Novo Nordisk | Phase 1 | SMN2 | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| TAK-2403 | Takeda | Phase 2 | WEE1 | |
| Lisorapivir | Takeda | Preclinical | WRN | |
| REG-7737 | Regeneron | Preclinical | CD123 | |
| Ivosotorasib | Vertex Pharma | Preclinical | CD38 | |
| MRN-8133 | Moderna | Phase 2 | PD-1 |